Eff orts were attempted to create a bioequivalent Osmatic release tablet formulation of carbamazepine, with a drug release profi le comparable to that of the innovator product. Tablets were formulated using the wet granulation technique based on literature data and the innovative product’s characterization. It was discovered that the pioneer tablet had a fi lm coating. After reviewing the existing literature and patents, it was determined to use a non-infringing approach and create a fi lm-coated tablet with an equivalent bioavailability and dissolution profi le. Based of justifi cation, the optimized formulation has an F9 value of 90, which is excellent. The intention was to keep the same composition and only increase the size. Trial formulation 9’s formula and procedure fulfi lled the specifi ed physicochemical properties and dissolution profi le, which is equivalent to the reference product in various media, based on the results of several laboratory trials and evaluations. The extended-release was achieved by combining the rate-controlling polymer Natrosol 250L/Natrosol 250 H, a pH-dependent polymer, and Hypromellose. Compared to the innovator sample, the extended-release tablets were found to comply with the USP specifi cation. Stability tests on the optimised batch showed no major deviations, which is a positive result.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.